ClinicalTrials.gg
TerminatedNCT01420081Updated Jan 8, 2019Results posted

A Study Of Two Dual PI3K/mTOR Inhibitors, PF-04691502 And PF-05212384 In Patients With Recurrent Endometrial Cancer

A Phase 2 interventional study of PF-05212384 and PF-05212384 in Endometrial Neoplasms, sponsored by Pfizer. Terminated at 51 sites in 8 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-01-08.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Why this study was terminated
See termination reason in detailed description.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
67
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Endometrial Neoplasms by Pfizer — 2 open to participants now, 3 under way, 1 of them phase 3. Endometrial Neoplasms · Pfizer.

Enrollment
9th of 13
67 · median 88
Started
2012
the only one that year
Phase 2
3 of 13
none open now
Registered
1st of 13
by date

Among the 13 studies in Endometrial Neoplasms by Pfizer, this one is the 9th largest by enrollment, is the only one that started in 2012, is one of 3 in phase 2, and was the 1st registered.

Endometrial Neoplasms

1,428 studies on the registry are indexed under Endometrial Neoplasms; 472 are open to participants now.

Browse Endometrial Neoplasms studies →

Open to participants now

2 of the 13 studies in Endometrial Neoplasms by Pfizer are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 356 Endometrial Neoplasms studies recruiting now, 266 (75%) set no upper age limit and 54 (15%) stop at 75 or younger; 26 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Endometrial Neoplasms by Pfizer, or all of them as a file.
02

Study summary

This study will investigate the individual safety and efficacy of two dual PI3K/mTOR inhibitors in patients with recurrent endometrial cancer.

Read the detailed description

The study was prematurely discontinued due to lack confidence in the Stathmin assay as a patient selection criteria and subsequent lack of confidence in the efficacy signal that was observed. The decision to terminate the study was made on January 23, 2014. It should be noted that safety concerns have not been seen in this study and have not factored into this decision.

03

Conditions studied

  • Endometrial Neoplasms

Keywords

  • uterine neoplasms
  • endometrial
  • uterine
  • cancer
  • PI3K
  • mTOR
  • PI3K/mTOR
  • recurrent
  • metastatic
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Recurrent endometrial carcinoma
  • Disease progression following one or two with platinum containing chemotherapy
  • Tumor tissue available at time of screening for PI3K analysis
  • Adequate performance status
  • Adequate glucose control, bone marrow, kidney, liver, and heart function

Exclusion criteria

Exclusion Criteria:

  • More than 2 prior cytotoxic chemo regimens for endometrial carcinoma
  • Prior therapy with an agent known to be a PI3K, and or mTOR and or AKT inhibitor
  • Active
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
67 participants (actual)

Study arms

  • Experimental
    B

    PI3K Basal, IV Compound

    Drug: PF-05212384

  • Experimental
    C

    PI3K Activated, Oral Compound

    Drug: PF-05212384

  • Experimental
    F

    Japanese lead in cohort, IV compound

    Drug: PF-05212384

Interventions

06

What researchers measure

Primary outcomes

  1. Clinical Benefit Response for PF-04691502

    Clinical benefit response was defined as best overall response of complete response (CR), partial response (PR) or stable disease (SD) for at least 16 weeks from Cycle 1 Day 1 (C1D1) to the first time of disease progression. The outcome data table below presents the number of participants with clinical benefit response as "yes" or "no". On 09 Oct 2012, Pfizer decided to stop enrollment into PF-04691502. While tumor assessment for PF-04691502 was included as a listing in the final report, formal efficacy analysis for PF-04691502 was not performed.

    Time frame: 16 weeks from Cycle 1 Day 1

  2. Percentage of Participants With Clinical Benefit Response for PF-05212384

    Clinical benefit response was defined as best overall response of complete response (CR), partial response (PR) or stable disease (SD) for at least 16 weeks from Cycle 1 Day 1 (C1D1) to the first time of disease progression. The primary analysis is based on the clinical benefit rate which is calculated as proportion of participants with a clinical benefit response relative to total number of response evaluable participants. Per RECIST v1.1 for target lesions: CR defined as disappearance of all target lesions; PR defined as \>=30% decrease in the sum of the longest diameter of target lesions; SD does not qualify for CR, PR or Progression. All target lesions must be assessed. SD can follow PR only in the rare case that the sum increases by less than 20% from the nadir, but enough that a previously documented 30% decrease no longer holds. A Clopper-Pearson exact 95% CI for the clinical benefit rate is presented in the below table.

    Time frame: 16 weeks from Cycle 1 Day 1

Secondary outcomes

  1. Objective Response for PF-04691502

    Objective response is defined as CR or PR. CR: Complete response: 2 or more objective statuses of CR a minimum of 4 weeks apart documented before PD. Partial response: 2 or more objective statuses of PR or better a minimum of 4 weeks apart documented before PD, but not qualifying as CR. Per RECIST v1.1 for target lesions: CR defined as disappearance of all target lesions; PR defined as \>=30% decrease in the sum of the longest diameter of target lesions. The outcome data table below presents the number of participants with objective response as "yes" or "no". On 09 Oct 2012, Pfizer decided to stop enrollment into PF-04691502. While tumor assessment for PF-04691502 was included as a listing in the final report, formal efficacy analysis for PF-04691502 was not performed.

    Time frame: Randomization to objective progression, death or last tumor assessment without progression (up to 12 months)

  2. Percentage of Participants With Objective Response for PF-05212384

    Objective response is defined as CR or PR. CR: Complete response: 2 or more objective statuses of CR a minimum of 4 weeks apart documented before PD. Partial response: 2 or more objective statuses of PR or better a minimum of 4 weeks apart documented before PD, but not qualifying as CR. Per RECIST v1.1 for target lesions: CR defined as disappearance of all target lesions; PR defined as \>=30% decrease in the sum of the longest diameter of target lesions.

    Time frame: Randomization to objective progression, death or last tumor assessment without progression (up to 12 months)

  3. Progression Free Survival for PF-04691502

    PFS is defined as the time from the date of cycle 1 day 1 to the date that objective progressive disease is documented or death due to any cause, whichever occurs first. PFS was characterized in terms of the median. Approximate 95% confidence interval corresponding to this estimate was computed. Progression is defined using RECIST v1.1, as a 20% increase in the sum of the longest diameter of target lesions with a minimum absolute increase of 5 mm, or an unequivocal progression of non-target lesion, or the appearance of new lesions. On 09 Oct 2012, Pfizer decided to stop enrollment into PF-04691502. While tumor assessment for PF-04691502 was included as a listing in the final report, formal efficacy analysis for PF-04691502 was not performed.

    Time frame: From Cycle 1 Day 1 to objective progressive disease or death due to any cause whichever occurs first (up to 12 months)

  4. Progression Free Survival for PF-05212384

    PFS is defined as the time from the date of cycle 1 day 1 to the date that objective progressive disease is documented or death due to any cause, whichever occurs first. PFS was characterized in terms of the median. Approximate 95% confidence interval corresponding to this estimate was computed. Progression is defined using RECIST v1.1, as a 20% increase in the sum of the longest diameter of target lesions with a minimum absolute increase of 5 mm, or an unequivocal progression of non-target lesion, or the appearance of new lesions.

    Time frame: From Cycle 1 Day 1 to objective progressive disease or death due to any cause whichever occurs first (up to 12 months)

  5. Percentage of Participants With Progression Free Survival (PFS) at 6 Months for PF-05212384

    Progression free survival is defined as the time from the date of cycle 1 day 1 to the date that objective progressive disease is documented or death due to any cause, whichever occurs first. PFS was characterized in terms of the probability of remaining progression-free at 6 months (based on Kaplan-Meier estimates). Progression is defined using RECIST v1.1, as a 20% increase in the sum of the longest diameter of target lesions with a minimum absolute increase of 5 mm, or an unequivocal progression of non-target lesion, or the appearance of new lesions.

    Time frame: 6 months

  6. Overall Survival (OS) for PF-05212384

    OS is defined as the time from the date of Cycle 1 Day 1 to the date of death.

    Time frame: 12 months

  7. Level of Each Pharmacodynamic Parameter at Specified Timepoints- Glucose (mg/dL)

    PD biomarkers are measured at screening (baseline) and multiple time points post baseline. Baseline is defined as the last measurement prior to dosing, which is the measurement at screening or the cycle 1 day 1 pre-dose measurement if collected. This outcome measure will be updated once the data is available with the supplemental clinical study report.

    Time frame: Baseline (Day -3) and Cycle1 to Cycle 5 where each cycle consist of 28 days

  8. Level of Each Pharmacodynamic Parameter at Specified Timepoints- Insulin (UIU/mL)

    PD biomarkers are measured at screening (baseline) and multiple time points post baseline. Baseline is defined as the last measurement prior to dosing, which is the measurement at screening or the cycle 1 day 1 pre-dose measurement if collected. This outcome measure will be updated once the data is available with the supplemental clinical study report.

    Time frame: Baseline (Day -3) and Cycle1 to Cycle 5 where each cycle consist of 28 days

  9. Level of Each Pharmacodynamic Parameter at Specified Timepoints- Glycosylated Hemoglobin (HbA1c)

    PD biomarkers are measured at screening (baseline) and multiple time points post baseline. Baseline is defined as the last measurement prior to dosing, which is the measurement at screening or the cycle 1 day 1 pre-dose measurement if collected. This outcome measure will be updated once the data is available with the supplemental clinical study report.

    Time frame: Baseline (Day -3) and Cycle1 to Cycle 5 where each cycle consist of 28 days

  10. Level of Each Pharmacodynamic Parameter at Specified Timepoints- Cholesterol (mg/dL)

    PD biomarkers are measured at screening (baseline) and multiple time points post baseline. Baseline is defined as the last measurement prior to dosing, which is the measurement at screening or the cycle 1 day 1 pre-dose measurement if collected. This outcome measure will be updated once the data is available with the supplemental clinical study report.

    Time frame: Baseline (Day -3) and Cycle1 to Cycle 3 where each cycle consist of 28 days

  11. Level of Each Pharmacodynamic Parameter at Specified Timepoints- Triglycerides (mg/dL)

    PD biomarkers are measured at screening (baseline) and multiple time points post baseline. Baseline is defined as the last measurement prior to dosing, which is the measurement at screening or the cycle 1 day 1 pre-dose measurement if collected. This outcome measure will be updated once the data is available with the supplemental clinical study report.

    Time frame: Baseline (Day -3) and Cycle1 to Cycle 3 where each cycle consist of 28 days

  12. Stathmin H Score [Mean (SD)] for Each Treatment Arm With Gene and/or Protein Expression Biomarkers in Biopsied Tumor Tissue

    Gene and/or protein expression biomarkers in biopsied tumor tissue relating to PI3K and/or mTOR pathway activation, such as PIK3CA and PIK3R1 mutations, PTEN protein levels, and PIK3CA gene amplification were to be assessed. Each slide was imaged by whole slide scanning and patient samples were scored as follows: * Pathologist manual score (0, 1+, 2+, 3+) for overall staining intensity of tumor tissue. * Percentage of positive tumor cells staining at 0, 1+, 2+, and 3+. * H-score value (integer between 0 and 300) for tumor cell staining was calculated. The higher the stathmin staining, the higher the stathmin H-score.

    Time frame: Prior to Cycle 1 Day 1

  13. Percentage of Participants in Each Treatment Arm With Gene and/or Protein Expression Biomarkers- PIK3CA Amplification, KRAS Mutation P/N, KRAS Mutation OBSV, PTEN Stroma Manual Score, PTEN Tumor Manual Score, KRAS SCC and Stathmin H/L,Tissue.

    Gene and/or protein expression biomarkers in biopsied tumor tissue relating to PI3K and/or mTOR pathway activation, such as PIK3CA and PIK3R1 mutations, Phosphatase And Tensin Homolog (PTEN) protein levels, and PIK3CA gene amplification were to be assessed. Stained tissues were evaluated by a board-certified pathologist who provided a manual pathology score (i.e., 0, 1+, 2+, or 3+) and, if appropriate, comments upon the staining of the specimen. The directionality increases from 0 to 3+ with 0 being no staining for PTEN by IHC and 3+ being high staining intensity for PTEN.

    Time frame: Baseline and Cycle1 to Cycle 5 where each cycle consist of 28 days

  14. Area Under the Serum Concentration Time Profile From Time Zero Extrapolated to Infinity (AUCinf) of PF-05212384 at Each Specified Time Points.

    Time frame: Pre-dose: 0 hours, and Post dose: 0.5 (after end of infusion), 1, 2, 4, 6, 24, 72, and 120 hours at Day 1

  15. Area Under the Serum Concentration Time Profile From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of PF-05212384 at Each Specified Time Points.

    Time frame: Pre-dose: 0 hours, and Post dose: 0.5 (after end of infusion), 1, 2, 4, 6, 24, 72, and 120 hours at Day 1

  16. Maximum Plasma Concentration (Cmax) of PF-05212384 at Each Specified Time Points.

    Time frame: Pre-dose: 0 hours, and Post dose: 0.5 (after end of infusion), 1, 2, 4, 6, 24, 72, and 120 hours at Day 1

  17. Terminal Elimination Half Life (t½) of PF-05212384 at Each Specified Time Points.

    Time frame: Pre-dose: 0 hours, and Post dose: 0.5 (after end of infusion), 1, 2, 4, 6, 24, 72, and 120 hours at Day 1

  18. Time for Cmax (Tmax) of PF-05212384 at Each Specified Time Points.

    Time frame: Pre-dose: 0 hours, and Post dose: 0.5 (after end of infusion), 1, 2, 4, 6, 24, 72, and 120 hours at Day 1

  19. Clearance (CL) of PF-05212384 at Each Specified Time Points.

    Time frame: Pre-dose: 0 hours, and Post dose: 0.5 (after end of infusion), 1, 2, 4, 6, 24, 72, and 120 hours at Day 1

  20. Steady State Volume of Distribution (Vss) of PF-05212384 at Each Specified Time Points.

    Time frame: Pre-dose: 0 hours, and Post dose: 0.5 (after end of infusion), 1, 2, 4, 6, 24, 72, and 120 hours

  21. Number of Treatment-emergent Adverse Events (TEAEs) - All Causalities

    Safety of participants in terms of TEAEs. Note: One subject treated with PF-05212384 had the stathmin status changed after randomization and was categorized under the corresponding arm.

    Time frame: From baseline (-3 days) until 35 days post last dose

  22. Summary of Treatment-emergent Adverse Events (TEAEs) - All Causalities

    Safety of participants in terms of TEAEs. Note: One subject treated with PF-05212384 had the stathmin status changed after randomization and was categorized under the corresponding arm.

    Time frame: From baseline (-3 days) until 35 days post last dose

  23. Number of Treatment-related TEAEs

    Safety of subject in terms of number of participants with treatment related AEs. Note: One subject treated with PF-05212384 had the stathmin status changed after randomization and was categorized under the corresponding arm.

    Time frame: From baseline (-3 days) until 35 days post last dose

  24. Summary of Treatment-related TEAEs

    Safety of subject in terms of number of participants with treatment related AEs. Note: One subject treated with PF-05212384 had the stathmin status changed after randomization and was categorized under the corresponding arm.

    Time frame: From baseline (-3 days) until 35 days post last dose

07

Results

Posted May 19, 2015

Participant flow

An open-label, Phase 2, four-arm, non-comparative study to assess the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of PF-04691502 (an oral PI3K/mTOR inhibitor) and PF-05212384 (an Intravenous \[IV\] Phosphoinositide 3-Kinase \[PI3K\]/Mammalian Target of Rapamycin \[mTOR\] inhibitor).

Participant flow — Overall Study
MilestonePF-04691502 8 mg (PI3K Basal)PF-04691502 6 mg (PI3K Basal)PF-04691502 8 mg (PI3K Activated)PF-04691502 6 mg (PI3K Activated)PF-05212384 154 mg (PI3K Basal)PF-05212384 154 mg (PI3K Activated)Lead-in-cohort (LIC) PF-04691502 (4 mg)LIC PF-05212384 (89 mg)LIC PF-05212384 (154 mg)
Started311132020333
Completed000000000
Not completed311132020333
Withdrew: Death1080712011
Withdrew: Lost to follow-up000011000
Withdrew: Study terminated by sponsor2113117322
Withdrew: Subject refused futher follow-up001010000
Withdrew: Other reasons001000000

Outcome measures

PrimaryClinical Benefit Response for PF-04691502

Clinical benefit response was defined as best overall response of complete response (CR), partial response (PR) or stable disease (SD) for at least 16 weeks from Cycle 1 Day 1 (C1D1) to the first time of disease progression. The outcome data table below presents the number of participants with clinical benefit response as "yes" or "no". On 09 Oct 2012, Pfizer decided to stop enrollment into PF-04691502. While tumor assessment for PF-04691502 was included as a listing in the final report, formal efficacy analysis for PF-04691502 was not performed.

Time frame:
16 weeks from Cycle 1 Day 1
Reported as:
Number · Participants
Clinical Benefit Response for PF-04691502
ParticipantsPF-04691502 (PI3K Basal)PF-04691502 (PI3K Activated)
Participants with "Yes" response10
Participants with "No" response311
PrimaryPercentage of Participants With Clinical Benefit Response for PF-05212384

Clinical benefit response was defined as best overall response of complete response (CR), partial response (PR) or stable disease (SD) for at least 16 weeks from Cycle 1 Day 1 (C1D1) to the first time of disease progression. The primary analysis is based on the clinical benefit rate which is calculated as proportion of participants with a clinical benefit response relative to total number of response evaluable participants. Per RECIST v1.1 for target lesions: CR defined as disappearance of all target lesions; PR defined as \>=30% decrease in the sum of the longest diameter of target lesions; SD does not qualify for CR, PR or Progression. All target lesions must be assessed. SD can follow PR only in the rare case that the sum increases by less than 20% from the nadir, but enough that a previously documented 30% decrease no longer holds. A Clopper-Pearson exact 95% CI for the clinical benefit rate is presented in the below table.

Time frame:
16 weeks from Cycle 1 Day 1
Reported as:
Number · Percentage of participants
Percentage of Participants With Clinical Benefit Response for PF-05212384
Percentage of participantsPF-05212384 (PI3K Basal)PF-05212384 (PI3K Activated)PF-05212384 (PI3K Basal + Activated)
Percentage of Participants With Clinical Benefit Response for PF-0521238452.6 (28.9 to 75.6)26.3 (9.1 to 51.2)39.5 (24.0 to 56.6)
SecondaryObjective Response for PF-04691502

Objective response is defined as CR or PR. CR: Complete response: 2 or more objective statuses of CR a minimum of 4 weeks apart documented before PD. Partial response: 2 or more objective statuses of PR or better a minimum of 4 weeks apart documented before PD, but not qualifying as CR. Per RECIST v1.1 for target lesions: CR defined as disappearance of all target lesions; PR defined as \>=30% decrease in the sum of the longest diameter of target lesions. The outcome data table below presents the number of participants with objective response as "yes" or "no". On 09 Oct 2012, Pfizer decided to stop enrollment into PF-04691502. While tumor assessment for PF-04691502 was included as a listing in the final report, formal efficacy analysis for PF-04691502 was not performed.

Time frame:
Randomization to objective progression, death or last tumor assessment without progression (up to 12 months)
Reported as:
Number · Participants response
Objective Response for PF-04691502
Participants responsePF-04691502 (PI3K Basal)PF-04691502 (PI3K Activated)
Participants with "Yes" response00
Participants with "No" response411
SecondaryPercentage of Participants With Objective Response for PF-05212384

Objective response is defined as CR or PR. CR: Complete response: 2 or more objective statuses of CR a minimum of 4 weeks apart documented before PD. Partial response: 2 or more objective statuses of PR or better a minimum of 4 weeks apart documented before PD, but not qualifying as CR. Per RECIST v1.1 for target lesions: CR defined as disappearance of all target lesions; PR defined as \>=30% decrease in the sum of the longest diameter of target lesions.

Time frame:
Randomization to objective progression, death or last tumor assessment without progression (up to 12 months)
Reported as:
Number · Percentage of participants
Percentage of Participants With Objective Response for PF-05212384
Percentage of participantsPF-05212384 (PI3K Basal)PF-05212384 (PI3K Activated)PF-05212384 (PI3K Basal + Activated)
Percentage of Participants With Objective Response for PF-0521238421.1 (6.1 to 45.6)15.8 (3.4 to 39.6)18.4 (7.7 to 34.3)
SecondaryProgression Free Survival for PF-04691502

PFS is defined as the time from the date of cycle 1 day 1 to the date that objective progressive disease is documented or death due to any cause, whichever occurs first. PFS was characterized in terms of the median. Approximate 95% confidence interval corresponding to this estimate was computed. Progression is defined using RECIST v1.1, as a 20% increase in the sum of the longest diameter of target lesions with a minimum absolute increase of 5 mm, or an unequivocal progression of non-target lesion, or the appearance of new lesions. On 09 Oct 2012, Pfizer decided to stop enrollment into PF-04691502. While tumor assessment for PF-04691502 was included as a listing in the final report, formal efficacy analysis for PF-04691502 was not performed.

Time frame:
From Cycle 1 Day 1 to objective progressive disease or death due to any cause whichever occurs first (up to 12 months)
Reported as:
Number · Time to Event (Days)
Progression Free Survival for PF-04691502
Time to Event (Days)PF-04691502 (PI3K Basal)PF-04691502 (PI3K Activated)
Participant 110
Participant 21080
Participant 3500
Participant 41990
Participant 5054
Participant 6055
Participant 7051
Participant 801
Participant 9054
Participant 10062
Participant 11053
Participant 120105
Participant 1301
Participant 14054
Participant 15054
SecondaryProgression Free Survival for PF-05212384

PFS is defined as the time from the date of cycle 1 day 1 to the date that objective progressive disease is documented or death due to any cause, whichever occurs first. PFS was characterized in terms of the median. Approximate 95% confidence interval corresponding to this estimate was computed. Progression is defined using RECIST v1.1, as a 20% increase in the sum of the longest diameter of target lesions with a minimum absolute increase of 5 mm, or an unequivocal progression of non-target lesion, or the appearance of new lesions.

Time frame:
From Cycle 1 Day 1 to objective progressive disease or death due to any cause whichever occurs first (up to 12 months)
Reported as:
Median · Days
Progression Free Survival for PF-05212384
DaysPF-05212384 (PI3K Basal)PF-05212384 (PI3K Activated)PF-05212384 (PI3K Basal + Activated)
Progression Free Survival for PF-05212384112.0 (59.0 to 167.0)89.0 (56.0 to 172.0)108.0 (62.0 to 149.0)
SecondaryPercentage of Participants With Progression Free Survival (PFS) at 6 Months for PF-05212384

Progression free survival is defined as the time from the date of cycle 1 day 1 to the date that objective progressive disease is documented or death due to any cause, whichever occurs first. PFS was characterized in terms of the probability of remaining progression-free at 6 months (based on Kaplan-Meier estimates). Progression is defined using RECIST v1.1, as a 20% increase in the sum of the longest diameter of target lesions with a minimum absolute increase of 5 mm, or an unequivocal progression of non-target lesion, or the appearance of new lesions.

Time frame:
6 months
Reported as:
Number · Percentage of participants
Percentage of Participants With Progression Free Survival (PFS) at 6 Months for PF-05212384
Percentage of participantsPF-05212384 (PI3K Basal)PF-05212384 (PI3K Activated)PF-05212384 (PI3K Basal + Activated)
Percentage of Participants With Progression Free Survival (PFS) at 6 Months for PF-0521238423.2 (7.3 to 44.1)25.0 (7.8 to 47.2)24.3 (11.6 to 39.5)
SecondaryOverall Survival (OS) for PF-05212384

OS is defined as the time from the date of Cycle 1 Day 1 to the date of death.

Time frame:
12 months

No measurements were reported for this outcome.

SecondaryLevel of Each Pharmacodynamic Parameter at Specified Timepoints- Glucose (mg/dL)

PD biomarkers are measured at screening (baseline) and multiple time points post baseline. Baseline is defined as the last measurement prior to dosing, which is the measurement at screening or the cycle 1 day 1 pre-dose measurement if collected. This outcome measure will be updated once the data is available with the supplemental clinical study report.

Time frame:
Baseline (Day -3) and Cycle1 to Cycle 5 where each cycle consist of 28 days
Reported as:
Mean · Glucose (mg/dL)
Level of Each Pharmacodynamic Parameter at Specified Timepoints- Glucose (mg/dL)
Glucose (mg/dL)PF-05212384 (PI3K Basal)PF-05212384 (PI3K Activated)PF-05212384 (PI3K Basal + Activated)
Baseline98.5 ± 12.76101.7 ± 26.56100.1 ± 20.60
Cycle 1 Day 15 (n=18,17,35)105.3 ± 18.44117.2 ± 61.04111.1 ± 44.26
Cycle 1 Day 22 (n=2,1,3)103.0 ± 16.34120.1 ± 0108.7 ± 15.19
Cycle 2 Day 1 (n=17,14,31)103.7 ± 19.31114.0 ± 39.42108.3 ± 29.99
Cycle 2 Day 15 (n=17,8,25)104.8 ± 13.94106.4 ± 19.36105.3 ± 15.47
Cycle 3 Day 1 (n=14,10,24)100.6 ± 16.29125.9 ± 74.50111.1 ± 49.85
Cycle 4 Day 1 (n=12,7,19)96.3 ± 10.4098.9 ± 10.2097.3 ± 10.12
Cycle 5 Day 1 (n=9,4,13)103.2 ± 15.17112.2 ± 24.37106.0 ± 17.90
SecondaryLevel of Each Pharmacodynamic Parameter at Specified Timepoints- Insulin (UIU/mL)

PD biomarkers are measured at screening (baseline) and multiple time points post baseline. Baseline is defined as the last measurement prior to dosing, which is the measurement at screening or the cycle 1 day 1 pre-dose measurement if collected. This outcome measure will be updated once the data is available with the supplemental clinical study report.

Time frame:
Baseline (Day -3) and Cycle1 to Cycle 5 where each cycle consist of 28 days
Reported as:
Mean · Insulin (UIU/mL)
Level of Each Pharmacodynamic Parameter at Specified Timepoints- Insulin (UIU/mL)
Insulin (UIU/mL)PF-05212384 (PI3K Basal)PF-05212384 (PI3K Activated)PF-05212384 (PI3K Basal + Activated)
Baseline15.2 ± 12.6814.4 ± 7.0314.8 ± 10.36
Cycle 1 Day 15 (n=16,12,28)23.6 ± 14.6935.9 ± 37.0528.9 ± 26.79
Cycle 1 Day 22 (n=2,1,3)57.6 ± 51.1829.1 ± 048.1 ± 39.75
Cycle 2 Day 1 (n=17,10,27)30.3 ± 28.9228.9 ± 27.8529.8 ± 27.99
Cycle 2 Day 15 (n=14,6,20)28.2 ± 29.5621.9 ± 10.4926.3 ± 25.21
Cycle 3 Day 1 (n=13,9,22)20.7 ± 13.6535.1 ± 38.6626.6 ± 26.99
Cycle 4 Day 1 (n=11,6,17)17.1 ± 10.0424.8 ± 32.3219.8 ± 20.10
Cycle 5 Day 1 (n=7,4,11)17.0 ± 15.5615.7 ± 6.2016.5 ± 12.54
SecondaryLevel of Each Pharmacodynamic Parameter at Specified Timepoints- Glycosylated Hemoglobin (HbA1c)

PD biomarkers are measured at screening (baseline) and multiple time points post baseline. Baseline is defined as the last measurement prior to dosing, which is the measurement at screening or the cycle 1 day 1 pre-dose measurement if collected. This outcome measure will be updated once the data is available with the supplemental clinical study report.

Time frame:
Baseline (Day -3) and Cycle1 to Cycle 5 where each cycle consist of 28 days
Reported as:
Mean · HbA1c (mg/dL)
Level of Each Pharmacodynamic Parameter at Specified Timepoints- Glycosylated Hemoglobin (HbA1c)
HbA1c (mg/dL)PF-05212384 (PI3K Basal)PF-05212384 (PI3K Activated)PF-05212384 (PI3K Basal + Activated)
Baseline (n=15,14,29)7.8 ± 8.587.5 ± 6.157.7 ± 7.37
Cycle 1 Day 15 (n=4,2,6)14.7 ± 19.007.1 ± 1.3412.2 ± 15.25
Cycle 2 Day 1 (n=15,13,28)8.4 ± 9.666.7 ± 1.167.6 ± 7.05
Cycle 2 Day 15 (n=3,0,3)6.7 ± 0.71NA ± NA6.7 ± 0.71
Cycle 3 Day 1 (n=10,4,14)6.0 ± 0.787.3 ± 1.706.4 ± 1.19
Cycle 4 Day 1 (n=12,7,19)8.9 ± 10.136.9 ± 1.058.2 ± 8.01
Cycle 5 Day 1 (n=8,2,10)5.9 ± 0.8931.5 ± 36.0611.0 ± 16.17
SecondaryLevel of Each Pharmacodynamic Parameter at Specified Timepoints- Cholesterol (mg/dL)

PD biomarkers are measured at screening (baseline) and multiple time points post baseline. Baseline is defined as the last measurement prior to dosing, which is the measurement at screening or the cycle 1 day 1 pre-dose measurement if collected. This outcome measure will be updated once the data is available with the supplemental clinical study report.

Time frame:
Baseline (Day -3) and Cycle1 to Cycle 3 where each cycle consist of 28 days
Reported as:
Mean · Cholesterol (mg/dL)
Level of Each Pharmacodynamic Parameter at Specified Timepoints- Cholesterol (mg/dL)
Cholesterol (mg/dL)PF-05212384 (PI3K Basal)PF-05212384 (PI3K Activated)PF-05212384 (PI3K Basal + Activated)
Baseline (n=11,4,15)213 ± 54.48186.5 ± 52.43205.9 ± 53.45
Cycle 1 Day 28 (n=15,7,22)214.9 ± 49.15161.6 ± 86.51198.0 ± 66.28
Cycle 2 Day 28 (n=16,6,22)229.8 ± 44.31127.9 ± 108.69202.0 ± 79.83
Cycle 3 Day 28 (n=11,4,15)230.5 ± 48.63137.6 ± 107.02205.7 ± 77.15
SecondaryLevel of Each Pharmacodynamic Parameter at Specified Timepoints- Triglycerides (mg/dL)

PD biomarkers are measured at screening (baseline) and multiple time points post baseline. Baseline is defined as the last measurement prior to dosing, which is the measurement at screening or the cycle 1 day 1 pre-dose measurement if collected. This outcome measure will be updated once the data is available with the supplemental clinical study report.

Time frame:
Baseline (Day -3) and Cycle1 to Cycle 3 where each cycle consist of 28 days
Reported as:
Mean · Triglycerides (mg/dL)
Level of Each Pharmacodynamic Parameter at Specified Timepoints- Triglycerides (mg/dL)
Triglycerides (mg/dL)PF-05212384 (PI3K Basal)PF-05212384 (PI3K Activated)PF-05212384 (PI3K Basal + Activated)
Baseline (n=11,4,15)104.2 ± 40.95133.4 ± 25.75112.0 ± 38.96
Cycle 1 Day 28 (n=15,7,22)136.9 ± 70.03134.5 ± 57.21136.1 ± 64.85
Cycle 2 Day 28 (n=16,6,22)133.2 ± 71.40117.1 ± 62.77128.8 ± 68.07
Cycle 3 Day 28 (n=10,4,14)119.9 ± 64.22130.4 ± 58.01122.9 ± 60.47
SecondaryStathmin H Score [Mean (SD)] for Each Treatment Arm With Gene and/or Protein Expression Biomarkers in Biopsied Tumor Tissue

Gene and/or protein expression biomarkers in biopsied tumor tissue relating to PI3K and/or mTOR pathway activation, such as PIK3CA and PIK3R1 mutations, PTEN protein levels, and PIK3CA gene amplification were to be assessed. Each slide was imaged by whole slide scanning and patient samples were scored as follows: * Pathologist manual score (0, 1+, 2+, 3+) for overall staining intensity of tumor tissue. * Percentage of positive tumor cells staining at 0, 1+, 2+, and 3+. * H-score value (integer between 0 and 300) for tumor cell staining was calculated. The higher the stathmin staining, the higher the stathmin H-score.

Time frame:
Prior to Cycle 1 Day 1
Reported as:
Mean · Score
Stathmin H Score [Mean (SD)] for Each Treatment Arm With Gene and/or Protein Expression Biomarkers in Biopsied Tumor Tissue
ScorePF-05212384 (PI3K Basal)PF-05212384 (PI3K Activated)PF-05212384 (PI3K Basal + Activated)
Stathmin H Score [Mean (SD)] for Each Treatment Arm With Gene and/or Protein Expression Biomarkers in Biopsied Tumor Tissue96.4 ± 33.76201.3 ± 34.87146.2 ± 62.9
SecondaryPercentage of Participants in Each Treatment Arm With Gene and/or Protein Expression Biomarkers- PIK3CA Amplification, KRAS Mutation P/N, KRAS Mutation OBSV, PTEN Stroma Manual Score, PTEN Tumor Manual Score, KRAS SCC and Stathmin H/L,Tissue.

Gene and/or protein expression biomarkers in biopsied tumor tissue relating to PI3K and/or mTOR pathway activation, such as PIK3CA and PIK3R1 mutations, Phosphatase And Tensin Homolog (PTEN) protein levels, and PIK3CA gene amplification were to be assessed. Stained tissues were evaluated by a board-certified pathologist who provided a manual pathology score (i.e., 0, 1+, 2+, or 3+) and, if appropriate, comments upon the staining of the specimen. The directionality increases from 0 to 3+ with 0 being no staining for PTEN by IHC and 3+ being high staining intensity for PTEN.

Time frame:
Baseline and Cycle1 to Cycle 5 where each cycle consist of 28 days
Reported as:
Number · Percentage of participants
Percentage of Participants in Each Treatment Arm With Gene and/or Protein Expression Biomarkers- PIK3CA Amplification, KRAS Mutation P/N, KRAS Mutation OBSV, PTEN Stroma Manual Score, PTEN Tumor Manual Score, KRAS SCC and Stathmin H/L,Tissue.
Percentage of participantsPF-05212384 (PI3K Basal)PF-05212384 (PI3K Activated)PF-05212384 (PI3K Basal + Activated)
PIK3CA Amplification, Amplified (n=17,15,32)5.9 ± 33.766.7 ± 34.876.3 ± 62.9
PIK3CA Amplification, Nonamplified (n=17,15,32)94.193.393.8
KRAS Mutation, Positive (n=21,18,39)19.05.612.8
KRAS Mutation, Negative (n=21,18,39)81.094.487.2
KRAS Mutation OBSV, Gly12Asp (n=4,1,5)25.010040.0
KRAS Mutation OBSV, Gly12Cys (n=4,1,5)25.0020.0
KRAS Mutation OBSV, Gly12Val (n=4,1,5)50.0040.0
PTEN Stroma Manual Score, 1+ (n=21,19,40)4.802.5
PTEN Stroma Manual Score, 2+ (n=21,19,40)28.626.327.5
PTEN Stroma Manual Score, 3+ (n=21,19,40)66.773.770.0
PTEN Tumor Manual Score, 0 (n=21,19,40)23.821.122.5
PTEN Tumor Manual Score, 1+ (n=21,19,40)38.131.635.0
PTEN Tumor Manual Score, 2+ (n=21,19,40)38.147.442.5
KRAS SCC, Acceptable (n=21,18,39)100100100
Stathmin H/L,Tissue, High (n=21,19,40)010047.5
Stathmin H/L,Tissue, Low (n=21,19,40)100052.5
SecondaryArea Under the Serum Concentration Time Profile From Time Zero Extrapolated to Infinity (AUCinf) of PF-05212384 at Each Specified Time Points.
Time frame:
Pre-dose: 0 hours, and Post dose: 0.5 (after end of infusion), 1, 2, 4, 6, 24, 72, and 120 hours at Day 1
Reported as:
Geometric mean · ng.hr/mL
Area Under the Serum Concentration Time Profile From Time Zero Extrapolated to Infinity (AUCinf) of PF-05212384 at Each Specified Time Points.
ng.hr/mLPF-05212384 (PI3K Basal)PF-05212384 (PI3K Activated)
Area Under the Serum Concentration Time Profile From Time Zero Extrapolated to Infinity (AUCinf) of PF-05212384 at Each Specified Time Points.15280 ± 2414870 ± 40
SecondaryArea Under the Serum Concentration Time Profile From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of PF-05212384 at Each Specified Time Points.
Time frame:
Pre-dose: 0 hours, and Post dose: 0.5 (after end of infusion), 1, 2, 4, 6, 24, 72, and 120 hours at Day 1
Reported as:
Geometric mean · ng.hr/mL
Area Under the Serum Concentration Time Profile From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of PF-05212384 at Each Specified Time Points.
ng.hr/mLPF-05212384 (PI3K Basal)PF-05212384 (PI3K Activated)
Area Under the Serum Concentration Time Profile From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of PF-05212384 at Each Specified Time Points.15080 ± 2415890 ± 52
SecondaryMaximum Plasma Concentration (Cmax) of PF-05212384 at Each Specified Time Points.
Time frame:
Pre-dose: 0 hours, and Post dose: 0.5 (after end of infusion), 1, 2, 4, 6, 24, 72, and 120 hours at Day 1
Reported as:
Geometric mean · ng/mL
Maximum Plasma Concentration (Cmax) of PF-05212384 at Each Specified Time Points.
ng/mLPF-05212384 (PI3K Basal)PF-05212384 (PI3K Activated)
Maximum Plasma Concentration (Cmax) of PF-05212384 at Each Specified Time Points.9078 ± 367057 ± 84
SecondaryTerminal Elimination Half Life (t½) of PF-05212384 at Each Specified Time Points.
Time frame:
Pre-dose: 0 hours, and Post dose: 0.5 (after end of infusion), 1, 2, 4, 6, 24, 72, and 120 hours at Day 1
Reported as:
Mean · hours
Terminal Elimination Half Life (t½) of PF-05212384 at Each Specified Time Points.
hoursPF-05212384 (PI3K Basal)PF-05212384 (PI3K Activated)
Terminal Elimination Half Life (t½) of PF-05212384 at Each Specified Time Points.35.02 ± 5.3234.09 ± 8.87
SecondaryTime for Cmax (Tmax) of PF-05212384 at Each Specified Time Points.
Time frame:
Pre-dose: 0 hours, and Post dose: 0.5 (after end of infusion), 1, 2, 4, 6, 24, 72, and 120 hours at Day 1
Reported as:
Median · hours
Time for Cmax (Tmax) of PF-05212384 at Each Specified Time Points.
hoursPF-05212384 (PI3K Basal)PF-05212384 (PI3K Activated)
Time for Cmax (Tmax) of PF-05212384 at Each Specified Time Points.0.525 (0.500 to 1.07)0.650 (0.500 to 1.08)
SecondaryClearance (CL) of PF-05212384 at Each Specified Time Points.
Time frame:
Pre-dose: 0 hours, and Post dose: 0.5 (after end of infusion), 1, 2, 4, 6, 24, 72, and 120 hours at Day 1
Reported as:
Geometric mean · L/hr
Clearance (CL) of PF-05212384 at Each Specified Time Points.
L/hrPF-05212384 (PI3K Basal)PF-05212384 (PI3K Activated)
Clearance (CL) of PF-05212384 at Each Specified Time Points.10.09 ± 2410.36 ± 40
SecondarySteady State Volume of Distribution (Vss) of PF-05212384 at Each Specified Time Points.
Time frame:
Pre-dose: 0 hours, and Post dose: 0.5 (after end of infusion), 1, 2, 4, 6, 24, 72, and 120 hours
Reported as:
Geometric mean · Litres
Steady State Volume of Distribution (Vss) of PF-05212384 at Each Specified Time Points.
LitresPF-05212384 (PI3K Basal)PF-05212384 (PI3K Activated)
Steady State Volume of Distribution (Vss) of PF-05212384 at Each Specified Time Points.165.6 ± 32174.9 ± 57
SecondaryNumber of Treatment-emergent Adverse Events (TEAEs) - All Causalities

Safety of participants in terms of TEAEs. Note: One subject treated with PF-05212384 had the stathmin status changed after randomization and was categorized under the corresponding arm.

Time frame:
From baseline (-3 days) until 35 days post last dose
Reported as:
Number · Number of AEs
Number of Treatment-emergent Adverse Events (TEAEs) - All Causalities
Number of AEsPF-05212384 (PI3K Basal)PF-05212384 (PI3K Activated)PF-05212384 (PI3K Basal + Activated)
Number of Treatment-emergent Adverse Events (TEAEs) - All Causalities244269513
SecondarySummary of Treatment-emergent Adverse Events (TEAEs) - All Causalities

Safety of participants in terms of TEAEs. Note: One subject treated with PF-05212384 had the stathmin status changed after randomization and was categorized under the corresponding arm.

Time frame:
From baseline (-3 days) until 35 days post last dose
Reported as:
Number · Number of participants
Summary of Treatment-emergent Adverse Events (TEAEs) - All Causalities
Number of participantsPF-05212384 (PI3K Basal)PF-05212384 (PI3K Activated)PF-05212384 (PI3K Basal + Activated)
Participants with AEs211839
Participants with Serious Adverse Events (SAEs)31013
Participants with Grade 3 or Grade 4 AEs71421
Participants with Grade 5 AEs112
Permanently Discontinued due to AEs156
Dose Reduced due to AEs156
Temporary Discontinuations due to AEs81016
SecondaryNumber of Treatment-related TEAEs

Safety of subject in terms of number of participants with treatment related AEs. Note: One subject treated with PF-05212384 had the stathmin status changed after randomization and was categorized under the corresponding arm.

Time frame:
From baseline (-3 days) until 35 days post last dose
Reported as:
Number · Number of AEs
Number of Treatment-related TEAEs
Number of AEsPF-05212384 (PI3K Basal)PF-05212384 (PI3K Activated)PF-05212384 (PI3K Basal + Activated)
Number of Treatment-related TEAEs158161319
SecondarySummary of Treatment-related TEAEs

Safety of subject in terms of number of participants with treatment related AEs. Note: One subject treated with PF-05212384 had the stathmin status changed after randomization and was categorized under the corresponding arm.

Time frame:
From baseline (-3 days) until 35 days post last dose
Reported as:
Number · Number of participants
Summary of Treatment-related TEAEs
Number of participantsPF-05212384 (PI3K Basal)PF-05212384 (PI3K Activated)PF-05212384 (PI3K Basal + Activated)
Participants with AEs211839
Participants with SAEs033
Participants with Grade 3 or Grade 4 AEs4913
Participants with Grade 5 AEs000
Permanently Discontinued due to AEs123
Dose Reduced due to AEs145
Temporary Discontinuations due to AEs6713

Adverse events

Collected over Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PF-04691502 8 mg (PI3K Basal)—3/5 (60%)5/5 (100%)
PF-04691502 6 mg (PI3K Basal)—1/1 (100%)1/1 (100%)
PF-04691502 8 mg (PI3K Activated)—7/9 (77.8%)9/9 (100%)
PF-04691502 6 mg (PI3K Activated)—1/3 (33.3%)3/3 (100%)
PF-05212384 154 mg (PI3K Basal)—3/21 (14.3%)21/21 (100%)
PF-05212384 154 mg (PI3K Activated)—10/19 (52.6%)18/19 (94.7%)
Lead-in-cohort (LIC) PF-04691502 (4 mg)—1/3 (33.3%)3/3 (100%)
LIC PF-05212384 (89 mg)—0/3 (0%)3/3 (100%)
LIC PF-05212384 (154 mg)—1/3 (33.3%)3/3 (100%)
Most frequent serious events
Showing 10 of 32
Most frequent serious events
EventPF-04691502 8 mg (PI3K Basal)PF-04691502 6 mg (PI3K Basal)PF-04691502 8 mg (PI3K Activated)PF-04691502 6 mg (PI3K Activated)PF-05212384 154 mg (PI3K Basal)PF-05212384 154 mg (PI3K Activated)Lead-in-cohort (LIC) PF-04691502 (4 mg)LIC PF-05212384 (89 mg)LIC PF-05212384 (154 mg)
Oral PainGastrointestinal disorders0/51/10/90/30/210/190/30/30/3
StomatitisGastrointestinal disorders0/51/11/90/30/210/190/30/30/3
UrticariaSkin and subcutaneous tissue disorders0/51/10/90/30/210/190/30/30/3
PneumonitisRespiratory, thoracic and mediastinal disorders2/50/12/90/30/210/190/30/30/3
Pneumocystis Jirovecii PneumoniaInfections and infestations0/50/10/90/30/210/191/30/30/3
Skin InfectionInfections and infestations0/50/10/90/30/210/190/30/31/3
Lymphocyte Count DecreasedInvestigations0/50/10/90/30/210/191/30/30/3
Pneumothorax SpontaneousRespiratory, thoracic and mediastinal disorders0/50/10/91/30/210/190/30/30/3
DiarrhoeaGastrointestinal disorders1/50/12/90/30/210/190/30/30/3
PneumoniaInfections and infestations1/50/12/90/30/210/190/30/30/3
Most frequent other events
Showing 10 of 223
Most frequent other events
EventPF-04691502 8 mg (PI3K Basal)PF-04691502 6 mg (PI3K Basal)PF-04691502 8 mg (PI3K Activated)PF-04691502 6 mg (PI3K Activated)PF-05212384 154 mg (PI3K Basal)PF-05212384 154 mg (PI3K Activated)Lead-in-cohort (LIC) PF-04691502 (4 mg)LIC PF-05212384 (89 mg)LIC PF-05212384 (154 mg)
AnaemiaBlood and lymphatic system disorders0/51/11/90/32/212/190/30/31/3
Dry MouthGastrointestinal disorders1/51/12/92/33/214/190/30/30/3
NauseaGastrointestinal disorders3/51/15/91/312/2110/191/33/33/3
StomatitisGastrointestinal disorders1/50/14/90/35/213/191/33/33/3
Neutrophil Count DecreasedInvestigations0/51/10/90/31/210/191/30/30/3
Platelet Count DecreasedInvestigations1/51/11/90/30/210/190/30/30/3
White Blood Cell Count DecreasedInvestigations0/51/10/90/31/210/190/30/30/3
HyperglycaemiaMetabolism and nutrition disorders5/50/17/90/34/213/192/30/31/3
HypokalaemiaMetabolism and nutrition disorders1/51/14/90/31/212/190/30/31/3
Oropharyngeal PainRespiratory, thoracic and mediastinal disorders0/50/10/90/32/213/190/30/33/3

Baseline characteristics

Age, Customized
Age, Customized(participants)PF-04691502 8 mg (PI3K Basal)PF-04691502 6 mg (PI3K Basal)PF-04691502 8 mg (PI3K Activated)PF-04691502 6 mg (PI3K Activated)PF-05212384 154 mg (PI3K Basal)PF-05212384 154 mg (PI3K Activated)Lead-in-cohort (LIC) PF-04691502 (4 mg)LIC PF-05212384 (89 mg)LIC PF-05212384 (154 mg)Total
< 18 years0000000000
18 - 44 years0000000101
45 - 64 years21439421228
>= 65 years1070111611138
Sex: Female, Male
Sex: Female, Male(Participants)PF-04691502 8 mg (PI3K Basal)PF-04691502 6 mg (PI3K Basal)PF-04691502 8 mg (PI3K Activated)PF-04691502 6 mg (PI3K Activated)PF-05212384 154 mg (PI3K Basal)PF-05212384 154 mg (PI3K Activated)Lead-in-cohort (LIC) PF-04691502 (4 mg)LIC PF-05212384 (89 mg)LIC PF-05212384 (154 mg)Total
Female31113202033367
Male0000000000
08

Study locations

51 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35233, United States
  • University of Alabama at Birmingham, IDS Pharmacy
    Birmingham, Alabama 35249, United States
  • University of Alabama at Birmingham
    Birmingham, Alabama 35249, United States
  • University of California Medical Center
    La Jolla, California 92037, United States
  • Moores UC San Diego Cancer Center
    La Jolla, California 92093, United States
  • University of California Medical Center
    San Diego, California 92103, United States
  • Mercy Hospital
    Miami, Florida 33133, United States
  • Mercy Research Institute
    Miami, Florida 33133, United States
  • University of Chicago Medical Center
    Chicago, Illinois 60637, United States
  • University of Chicago Medicine Comprehensive Cancer Center at Silver Cross Hospital
    New Lenox, Illinois 60451, United States
  • University of Kansas
    Fairway, Kansas 66205, United States
  • University of Kansas Hospital
    Kansas City, Kansas 66160, United States
  • University of Kansas Cancer Center and Medical Pavilion
    Westwood, Kansas 66205, United States
  • Mary Bird Perkins Cancer Center at St. Tammany Parish Hospital
    Covington, Louisiana 70433, United States
  • Women's Cancer Care
    Covington, Louisiana 70433, United States
  • Women's Cancer Care
    Metairie, Louisiana 70006, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
  • University of New Mexico Cancer Center
    Albuquerque, New Mexico 87106, United States
  • Peter MacCallum Cancer Centre, Division of Cancer Madicine
    East Melbourne, Victoria 3002, Australia
  • Foothills Medical Center
    Calgary, Alberta T2N 2T9, Canada
  • Tom Baker Cancer Centre
    Calgary, Alberta T2N 4N2, Canada
  • British Columbia Cancer Agency - Vancouver Centre
    Vancouver, British Columbia V5Z 4E6, Canada
  • Cancer Centre of Southeastern Ontario at Kingston General Hospital
    Kingston, Ontario K7L 5P9, Canada
  • Princess Margaret Hospital
    Toronto, Ontario M5G 2M9, Canada
  • Royal Victoria Hospital
    Montreal, Quebec H3A 1A1, Canada
  • Jewish General Hospital
    Montreal, Quebec H3T 1E2, Canada
  • St. Mary's Hospital
    Montreal, Quebec H3T 1M5, Canada
  • Aichi cancer center hospital
    Nagoya, Aichi 464-8681, Japan
  • Hyogo Cancer Center
    Akashi, Hyogo 673-8558, Japan
  • Saitama Medical University International Medical Center
    Hidaka, Saitama 350-1298, Japan
  • National Cancer Center Hospital
    Chuo-Ku, Tokyo 104-0045, Japan
  • Regionalny Osrodek Onkologiczny Wojewodzki Szpital Specjalistyczny im. M. Kopernika
    Lodz, 93-509, Poland
  • Zaklad Radiologii
    Lodz, 93-513, Poland
  • Centrum Onkologii Ziemi Lubelskiej im. Św. Jana z Dukli
    Lublin, 20-090, Poland
  • Federal State Healthcare Institution
    Lermontov, Stavropol Territory 357340, Russian Federation
  • Clinical Oncology Dispensary 1 of Department of Healthcare of the Krasnodar Region
    Krasnodar, 350040, Russian Federation
  • Pyatigorsk Oncology Center
    Pyatigorsk, 357502, Russian Federation
  • Saint Petersburg State Healthcare Institution City Clinical Oncology Dispensary
    Saint Petersburg, 198255, Russian Federation
  • Hospital Universitari Vall d'hebron
    Barcelona, 08035, Spain
  • Centro Oncologico MD Anderson Internacional España
    Madrid, 28033, Spain
  • Hospital Clinico San Carlos
    Madrid, 28040, Spain
  • Hospital Universitario La Paz
    Madrid, 28046, Spain
  • Fundacion Instituto Valenciano de Oncologia - I.V.O.
    Valencia, 46009, Spain
  • Fundacion Instituto Valenciano de Oncologia - I.V.O
    Valencia, 46009, Spain
  • The Royal Marsden NHS Foundation Trust
    Sutton, Surrey SM2 5PT, United Kingdom
  • Beatson Oncology Centre
    Glasgow, G12 0YN, United Kingdom
  • University College London Hospital NHS Foundation Trust
    London, NW1 2PG, United Kingdom
  • The Royal Marsden NHS Foundation Trust
    London, SW3 6JJ, United Kingdom
09

References and documents

Publications

  • Del Campo JM, Birrer M, Davis C, Fujiwara K, Gollerkeri A, Gore M, Houk B, Lau S, Poveda A, Gonzalez-Martin A, Muller C, Muro K, Pierce K, Suzuki M, Vermette J, Oza A. A randomized phase II non-comparative study of PF-04691502 and gedatolisib (PF-05212384) in patients with recurrent endometrial cancer. Gynecol Oncol. 2016 Jul;142(1):62-69. doi: 10.1016/j.ygyno.2016.04.019. Epub 2016 Apr 24. PubMed 27103175 ↗

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2012 to primary completion in Apr 2014, 27 months.

Results were first posted in May 2015, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 17, 2011
First posted
Aug 19, 2011
StartActual
Jan 19, 2012
Primary completionActual
Apr 30, 2014
CompletionActual
Dec 25, 2015
Results first posted
May 19, 2015
Last update
Jan 8, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 8, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01420081
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Aug 19, 2011
Start date
Jan 19, 2012
Primary completion
Apr 30, 2014
Completion
Dec 25, 2015
Results posted
May 19, 2015
Last update
Jan 8, 2019

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gedatolisib

Start the discussion